Form 6-K China Automotive Systems For: Nov 12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November, 2025

 

Commission File Number: 001-42851

 

China Automotive Systems, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

No. 1 Henglong Road, Yu Qiao Development Zone

Shashi District, Jing Zhou City, Hubei Province

The People’s Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F x    Form 40-F ¨

 

 

  

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On November 12, 2025, China Automotive Systems, Inc. (the “Company”) issued a press release titled “China Automotive Systems Reports 77.8% EPS Growth in the Third Quarter of 2025 and Raises Full Year Guidance“. A copy of the press release, and the unaudited third quarter 2025 results, are furnished as Exhibits 99.1 to this report on Form 6-K.

 

INDEX TO EXHIBITS

 

Exhibit No.	Description
99.1	November 12, 2025 press release with Third Quarter 2025 Condensed Unaudited Consolidated Financial Statements

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	China Automotive Systems, Inc.
Date: November 12, 2025	By:	/s/ Hanlin Chen
	Name:	Hanlin Chen
	Title:	Chairman

 

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Teleport Named Most Innovative Identity and Access Management Platform in 2026 Cybersecurity Stars Awards
• Real Canadian Superstore at Buffalo Run Set to Open This Fall
• In HelloNation, Medical Weight Loss Expert Patty Schultz Explains Semaglutide and Tirzepatide